Rezolute (NASDAQ:RZLT – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14), Zacks reports.
Rezolute Price Performance
RZLT opened at $5.08 on Friday. The business has a 50 day moving average price of $4.62 and a two-hundred day moving average price of $3.72. The company has a market capitalization of $203.89 million, a price-to-earnings ratio of -4.46 and a beta of 1.18. Rezolute has a 1-year low of $0.72 and a 1-year high of $6.10.
Analyst Ratings Changes
A number of equities research analysts have issued reports on RZLT shares. JMP Securities reiterated a “market outperform” rating and issued a $7.00 target price on shares of Rezolute in a research note on Friday. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Rezolute in a research note on Monday, September 9th. BTIG Research upped their target price on shares of Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Maxim Group lifted their price target on Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 6th. Finally, Craig Hallum began coverage on Rezolute in a report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $11.57.
About Rezolute
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Featured Articles
- Five stocks we like better than Rezolute
- Transportation Stocks Investing
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- The 3 Best Blue-Chip Stocks to Buy Now
- MarketBeat Week in Review – 9/16 – 9/20
- The Basics of Support and Resistance
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.